Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Phase 2 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics in patients with Parkinson's Disease

Next Previous
Trial Profile

The Phase 2 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics in patients with Parkinson's Disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Usnoflast (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use

Most Recent Events

  • 18 Jan 2024 New trial record
  • 16 Dec 2023 According to a Zydus Lifesciences media release, the company has received approval from USFDA, to initiate the Phase II clinical study of NLRP3 inhibitor ZYIL1 in patients with Parkinson's disease.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top